Screener
Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Gyre Pharmaceuticals | Gyre | Total |
|---|---|---|---|
| Operating expenses: | |||
| Cost of revenues | 1,151 | — | 1,151 |
| Selling and marketing | 15,195 | — | 15,195 |
| Research and development | 3,337 | 5,014 | 8,351 |
| General and administrative | 2,858 | 4,417 | 7,275 |
| Total segment operating expenses | 22,541 | 9,431 | 31,972 |
| Income (loss) from segment operations | 4,230 | (6,468) | (2,238) |
| Other segment (loss) income, net: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — research and development expense?
- Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — research and development expense of $9.7M in Q2 2026.
- What does gyre pharmaceuticals — research and development expense mean?
- This metric represents the total costs incurred by the pharmaceutical segment for research, clinical trials, and the development of drug candidates. It reflects the company's investment in advancing its pipeline, particularly for treatments like Hydronidone. High spending in this area indicates a commitment to long-term innovation and regulatory approval efforts.
Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude